Literature DB >> 18478341

Ethnic differences in prostate cancer survival in New Zealand: a national study.

Mary Jane Sneyd1.   

Abstract

OBJECTIVE: To examine disease-specific survival from prostate cancer by ethnic group in New Zealand.
METHODS: Analyses were based on the 7,733 men with histologically confirmed prostate cancer diagnosed from the start of 1996 to the end of 1999 in New Zealand. Five-year adjusted prostate-specific mortality rates and hazard ratios were calculated for Maori, Pacific, and European men.
RESULTS: In univariate analyses, Maori and Pacific men had higher mortality particularly in the first year after a diagnosis of prostate cancer than did European men. The strongest prognostic factors for prostate cancer were Gleason score and age. When survival analyses by ethnic group were adjusted for age and Gleason score the disparities in survival for Maori men and Pacific men with low-grade prostate cancers remained, with European men having the best survival.
CONCLUSIONS: Several possible explanations have been proposed to explain the survival disparities by ethnicity in New Zealand. Differentials in Gleason grade of disease by ethnic group explain a lot of these disparities. Further data on stage of disease at diagnosis, co-morbidity, treatment, access to health services, and behavioral and environmental factors are needed to resolve these issues.

Entities:  

Mesh:

Year:  2008        PMID: 18478341     DOI: 10.1007/s10552-008-9166-1

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  6 in total

1.  Uric acid: a modulator of prostate cells and activin sensitivity.

Authors:  Febbie Sangkop; Geeta Singh; Ely Rodrigues; Elspeth Gold; Andrew Bahn
Journal:  Mol Cell Biochem       Date:  2016-02-24       Impact factor: 3.396

2.  Treatment modalities for Māori and New Zealand European men with localised prostate cancer.

Authors:  Zuzana Obertová; Ross Lawrenson; Nina Scott; Michael Holmes; Charis Brown; Chunhuan Lao; Leanne Tyrie; Peter Gilling
Journal:  Int J Clin Oncol       Date:  2015-01-06       Impact factor: 3.402

3.  Analysis of Gleason grade and scores in 90 Nigerian Africans with prostate cancer during the period 1994 to 2004.

Authors:  U G Ugare; I E Bassey; P G Jibrin; I A Ekanem
Journal:  Afr Health Sci       Date:  2012-03       Impact factor: 0.927

4.  Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia.

Authors:  Jennifer C Rodger; Rajah Supramaniam; Alison J Gibberd; David P Smith; Bruce K Armstrong; Anthony Dillon; Dianne L O'Connell
Journal:  BJU Int       Date:  2015-04       Impact factor: 5.588

5.  Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.

Authors:  Zuzana Obertová; Nina Scott; Charis Brown; Fraser Hodgson; Alistair Stewart; Michael Holmes; Ross Lawrenson
Journal:  BMC Fam Pract       Date:  2014-08-26       Impact factor: 2.497

6.  Cysteine (C)-x-C receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells.

Authors:  Ayesha S Don-Salu-Hewage; Siu Yuen Chan; Kathleen M McAndrews; Mahandranauth A Chetram; Michelle R Dawson; Danaya A Bethea; Cimona V Hinton
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.